Search
for
Sort by
Research 301–330 of 1000+
- Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
- Dermatologic manifestations of COVID‐19: a comprehensive systematic review
- Chaos and antichaos in pathology
- Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
- Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge
- Physiologic changes and dermatoses of pregnancy
- INTERFERONS IN DERMATOLOGY
- Secondary cicatricial and other permanent alopecias
- ADVANCES IN PSORIASIS THERAPY
- Skin manifestations of chronic kidney disease
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Topical absorption and systemic toxicity
- Anticonvulsant-Induced Cutaneous Reactions
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Menopausal Acne – Challenges And Solutions
- Non-hemorrhage-related adverse effects of rivaroxaban
- Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach
- Psychoactive drugs and skin
- Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease‐19 (COVID‐19): A scoping review
- Drug eruptions in dermatology
- Clinical Development of Topoisomerase-Interactive Drugs
- Hair loss
- Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity
- Autoimmune gastritis and parietal cell reactivity in two children with abnormal intestinal permeability
- Fixed-Drug Eruption due to Dextromethorphan
- SUSPECTED CUTANEOUS DRUG TOXICITY IN RHEUMATOID ARTHRITIS—AN EVALUATION
- Adverse cutaneous effects of psychotropic medications
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma